Sirona Biochem faces financial challenges, closes French subsidiary
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/29/2026
- S&P 500, Nasdaq futures inch up before Fed decision; chip stocks wobble
- Oil rises as US-Iran tension escalates after Iraq strikes, missile attack
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- SK Hynix's record profit misses forecasts, shares slump 10% despite robust AI chip demand
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
- After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK
Sirona Biochem Update to Shareholders on Financial Status and Operations
August 1, 2025 4:30 PM EDTVANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (Sirona) wishes to provide shareholders with a critical update on the companys financial position and recent corporate developments.
The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-based management has operated without salary and has personally contributed funds to sustain essential operations.
After an extensive search... More
